Sprue-Like Enteropathy and Liver Injury : A Rare Emerging Association with Olmesartan
Olmesartan-induced enteropathy is an underreported phenomenon, first described in 2012. While olmesartan's antihypertensive properties were confirmed early on, its association with a sprue-like enteropathy was subsequently noted. Although this association has been reported with olmesartan, there have been few reports of this association with other angiotensin-receptor blockers. We present a case of a 79-year-old male who presented with diarrhea, weight loss, jaundice, and transaminitis. Further history revealed that he had been taking olmesartan 40 mg daily for hypertension. Workup of his diarrhea and jaundice included duodenal and liver biopsies revealed findings consistent with a sprue-like enteropathy and an autoimmune hepatitis-like pattern. On discontinuation of olmesartan, his 1-month follow-up revealed significant improvement in his clinical status as well as his liver function tests. Olmesartan is an effective antihypertensive medication; however, physicians must be mindful of its side effect of causing a sprue-like enteropathy and liver injury. Patients should be counseled on discontinuing olmesartan, and they should be started on an alternative therapy for hypertension.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:9 |
|---|---|
| Enthalten in: |
Journal of investigative medicine high impact case reports - 9(2021) vom: 01. Jan., Seite 23247096211037463 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Odak, Mihir [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
8W1IQP3U10 |
|---|
| Anmerkungen: |
Date Completed 15.10.2021 Date Revised 15.10.2021 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.1177/23247096211037463 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM329223836 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM329223836 | ||
| 003 | DE-627 | ||
| 005 | 20231225204642.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1177/23247096211037463 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1097.xml |
| 035 | |a (DE-627)NLM329223836 | ||
| 035 | |a (NLM)34378440 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Odak, Mihir |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Sprue-Like Enteropathy and Liver Injury |b A Rare Emerging Association with Olmesartan |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 15.10.2021 | ||
| 500 | |a Date Revised 15.10.2021 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Olmesartan-induced enteropathy is an underreported phenomenon, first described in 2012. While olmesartan's antihypertensive properties were confirmed early on, its association with a sprue-like enteropathy was subsequently noted. Although this association has been reported with olmesartan, there have been few reports of this association with other angiotensin-receptor blockers. We present a case of a 79-year-old male who presented with diarrhea, weight loss, jaundice, and transaminitis. Further history revealed that he had been taking olmesartan 40 mg daily for hypertension. Workup of his diarrhea and jaundice included duodenal and liver biopsies revealed findings consistent with a sprue-like enteropathy and an autoimmune hepatitis-like pattern. On discontinuation of olmesartan, his 1-month follow-up revealed significant improvement in his clinical status as well as his liver function tests. Olmesartan is an effective antihypertensive medication; however, physicians must be mindful of its side effect of causing a sprue-like enteropathy and liver injury. Patients should be counseled on discontinuing olmesartan, and they should be started on an alternative therapy for hypertension | ||
| 650 | 4 | |a Case Reports | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a liver injury | |
| 650 | 4 | |a olmesartan | |
| 650 | 4 | |a olmesartan-induced enteropathy | |
| 650 | 4 | |a sprue-like enteropathy | |
| 650 | 4 | |a transaminitis | |
| 650 | 7 | |a Imidazoles |2 NLM | |
| 650 | 7 | |a Tetrazoles |2 NLM | |
| 650 | 7 | |a olmesartan |2 NLM | |
| 650 | 7 | |a 8W1IQP3U10 |2 NLM | |
| 700 | 1 | |a Udongwo, Ndausung |e verfasserin |4 aut | |
| 700 | 1 | |a Alfraji, Nasam |e verfasserin |4 aut | |
| 700 | 1 | |a Zheng, Min |e verfasserin |4 aut | |
| 700 | 1 | |a Zaidi, Saddam |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of investigative medicine high impact case reports |d 2013 |g 9(2021) vom: 01. Jan., Seite 23247096211037463 |w (DE-627)NLM240776232 |x 2324-7096 |7 nnns |
| 773 | 1 | 8 | |g volume:9 |g year:2021 |g day:01 |g month:01 |g pages:23247096211037463 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1177/23247096211037463 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 9 |j 2021 |b 01 |c 01 |h 23247096211037463 | ||